An observational study in Pregnancy and Malaria, sponsored by Amivas (US), LLC. Recruiting at 1 site in United States. Open to female participants aged 15 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-01-30.
Sponsored by Amivas (US), LLC · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 105 studies in Malaria with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Malaria · United States.
Among the 105 studies in Malaria with a site in United States, this one is the 13th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2022, is one of 16 observational ones, and was the 93rd registered.
1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.
Browse Malaria studies →9 of the 105 studies in Malaria with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–54 · Healthy volunteers
Johns Hopkins Bloomberg School of Public Health · Sites in United States, Zambia
Ages 1 mo–59 mo
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–70 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18–50 · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 3+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.
This study: 15 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
105 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 73 · Phase 2 20 · Phase 3 2 · Phase 4 1
First in 1998; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 25 is below the median of 578 across 205 observational studies indexed under Malaria.
Median enrollment 45 across the 89 interventional studies, 324 across the 15 observational. Of the 92 that completed or were terminated, 22 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 105 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Amivas (US), LLC as lead sponsor.
Amivas (US), LLC has 1 study filed under Malaria — fewer than ten, so there is no comparison to draw.
3 of the studies in Malaria with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05711485Johns Hopkins Bloomberg School of Public HealthPlatelet-Directed Whole Blood Transfusion Strategy for Malaria | 2027-04-30 |
| NCT06854042Eisai Inc.A Study of Oral E1018 in Healthy Adult Participants | 2027-07-22 |
| NCT06607003National Institute of Allergy and Infectious Diseases (NIAID)Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays | 2027-11-26 |
Add all 3 to your calendar (.ics) → With an account.
Among the 105 studies in Malaria with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective observational study in which a female patient who received IV Artesunate while pregnant can volunteer to provide information about her pregnancy and the outcome of her pregnancy. Information will be collected from patient's provider, the patient's obstetrician, the child's pediatrician, or other relevant healthcare provider.
Pregnant women or physicians treating pregnant women with severe malaria with IV Artesunate will become aware of the Pregnancy Registry via the product label, the Amivas Inc. website, or her physician. By calling 1-855-526-4827 (1-855-5AMIVAS) or contacting www.amivas.com/our-products, the patient or physician will be connected to the Pregnancy Registry Call Center. In France, the Collaborating-Investigators conducting the ARTEMUM observatory study have a wide information campaign among obstetrical wards, neonatal wards, Infectious Diseases wards, intensive care units (ICU), and parasitology hospital laboratories, through expert networks of infectious diseases specialists, obstetricians and pediatricians in University hospitals from the Paris Area and suburbs that concentrate 50-55% of malaria cases in France. They also collaborate with the National Research Center (NRC) for malaria and will capture voluntary reports by clinicians and microbiologists in the NRC network.
When contact is made to the call center, a trained staff member will acquaint the patient or treating physician with the goals and procedures of the study. If the patient agrees to participate in the study over the telephone, the patient's verbal consent will be documented, and the patient will be sent the study Consent Form that includes the consent for the patient's physician/obstetrician and the child's pediatrician to release medical information via email. If a physician is contacting the Call Center, s/he may be provided with this form to review, and the physician will be directed to ask the patient to telephone the Call Center to provide consent. With the patient's consent, the patient's physician/obstetrician will be contacted by a Call Center staff member and will be interviewed by a trained call center healthcare professional/pharmacist for information about the patient including demographics, malaria history, history of treatment, and initial pregnancy data. The Call Center will contact the patient's physicians (including obstetrician and infant's pediatrician, as appropriate) each trimester until delivery, and also at birth and 1 year after birth, to collect data on maternal adverse events (AEs), pregnancy outcome, fetal outcome, and infant outcome. Patients consented in France under the ARTEMUM study will undergo the consent process by the treating Physician. Anonymized data will be prospectively collected by a research technician under the supervision of a local manager in France.
Data collected by the call center will be sent to the Coordinating Center on a monthly basis for review and tracking of participants, then annually for inclusion in the interim or final report. Data collected as part of the ARTEMUM study will be provided in aggregate as summary tables to be included in the annual report.
Pregnant women worldwide who were or are being treated with IV Artesunate who can be properly consented to provide personal health information on her pregnancy and agree to provide health information on her fetus, neonate, and infant child will be included in the study. Although IV Artesunate is indicated for the treatment of severe malaria, women who were treated off label for another indication who received IV Artesunate while pregnant will be included in the study as well.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Number of pregnant females with high blood pressure
Number of pregnant females with high blood pressure reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with severe nausea
Number of pregnant females with severe nausea reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with vomiting
Number of pregnant females with vomiting reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with dehydration
Number of pregnant females with dehydration reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with diabetes (newly occurring)
Number of pregnant females with diabetes (newly occurring) reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with obesity/marked weight gain
Number of pregnant females with obesity/marked weight gain reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with anemia (newly occurring)
Number of pregnant females with anemia (newly occurring) reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with kidney or bladder infections
Number of pregnant females with kidney or bladder infections reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with vaginal bleeding
Number of pregnant females with vaginal bleeding reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with abruptio placenta
Number of pregnant females with abruptio placenta reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with placenta previa
Number of pregnant females with placenta previa reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with premature rupture of membranes
Number of pregnant females with premature rupture of membranes reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with preterm labor
Number of pregnant females with preterm labor reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with ectopic pregnancy
Number of pregnant females with ectopic pregnancy reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with molar pregnancy
Number of pregnant females with molar pregnancy reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females who died
Number of pregnant females who died reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with spontaneous abortions/miscarriage
Number of pregnant females with spontaneous abortions/miscarriage reported in medical record
Time frame: Up to 20 weeks
Number of pregnant females with elective terminations
Number of pregnant females with elective terminations reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of fetal deaths/stillbirths
Number of fetal deaths/stillbirths reported in medical record
Time frame: From 20 weeks to study completion
Number of premature live births (<37 weeks)
Number of premature live births (\<37 weeks) reported in medical record
Time frame: Up to 37 weeks
Number pregnant females with with live term births
Number pregnant females with with live term births reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of pregnant females with normal vaginal delivery or C-section
Number of pregnant females with normal vaginal delivery or C-section reported in medical record
Time frame: Through study completion, an average of 40 weeks
Number of newborns with low birth weight (<2500 grams)
Number of newborns with low birth weight (\<2500 grams)
Time frame: At birth
Number of newborns with heart and circulation defects
Number of newborns with heart and circulation defects reported in medical record
Time frame: At birth
Number of newborns with genital and urinary tract defects
Number of newborns with genital and urinary tract defects reported in medical record
Time frame: At birth
Number of newborns with nervous system and eye defects
Number of newborns with nervous system and eye defects reported in medical record
Time frame: At birth
Number of newborns with Club foot
Number of newborns with Club foot reported in medical record
Time frame: At birth
Neonate mean body weight (kg)
Neonate mean body weight (kg)
Time frame: 1 month
Infant mean body weight (kg)
Infant mean body weight (kg)
Time frame: 12 months
Number of infants who sit unattended or without support
Number of infants who sit unattended or without support from medical record
Time frame: 12 months
Number of infants who pick up small objects with thumb-finger grasp
Number of infants who pick up small objects with thumb-finger grasp from medical record
Time frame: 12 months
Number of infants who say "Dada" or "Mama" nonspecifically
Number of infants who say "Dada" or "Mama" nonspecifically from medical record
Time frame: 12 months
Number of infants who look for dropped objects or objects hidden by parents
Number of infants who look for dropped objects or objects hidden by parents from medical record
Time frame: 12 months
Neonate mean body length (cm)
Neonate mean body length (cm)
Time frame: 1 month
Neonate mean head circumference (cm)
Neonate mean head circumference (cm)
Time frame: 1 month
Infant mean recumbent weight (kg)
Infant mean recumbent weight (kg)
Time frame: 12 months
Infant mean weight-for-length ratio (kg/cm)
Infant mean weight (kg) divided by body length (cm)
Time frame: 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Jun 2029, 84 months after the start.
Of 93 observational studies under Malaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 44. This study's planned 84 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.